Acrivon Therapeutics, Inc. SEC filings ACRV

Acrivon Therapeutics, Inc. has 346 filings in SEC EDGAR's recent list, going back to Feb 12, 2021. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 12, 2026 (results of operations). The company's fiscal year ends on December 31.

Acrivon Therapeutics, Inc. SEC filings
Form Description Filed Period
S-8 Employee stock plan registration Aug 12, 2026 —
S-8 Employee stock plan registration Mar 19, 2026 —
S-8 Employee stock plan registration May 14, 2025 —
S-8 Employee stock plan registration Mar 28, 2025 —
S-3 Shelf registration Apr 17, 2024 —
S-8 Employee stock plan registration Mar 29, 2024 —
S-3 Shelf registration Dec 1, 2023 —
S-8 Employee stock plan registration Aug 11, 2023 —
S-8 Employee stock plan registration Mar 29, 2023 —
S-8 Employee stock plan registration Nov 17, 2022 —
424B4 Prospectus Nov 16, 2022 —
S-1MEF Filing Nov 14, 2022 —
FWP Free writing prospectus Nov 14, 2022 —
S-1/A Amended registration statement Nov 8, 2022 —
S-1/A Amended registration statement Nov 3, 2022 —
S-1 Registration statement Oct 17, 2022 —

Showing 16 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
ACRV (Nasdaq)
Fiscal year ends
December 31
Headquarters
Watertown, MA
SEC filer status
, Emerging growth company
SEC CIK
1781174

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.